MSB

3.21%

$1.13 mesoblast limited

Mesoblast in Freefall, page-843

First 843 Last

Share
Profile

Follow
Sojourner

6,545 Posts.

1967

15/06/22

22:20

Post #: 62023753
Share

Originally posted by ukpdam ↑

some time ago when things were looking chipper on the near horizon I did a discounted cash flow on future expected earnings (the true value of a firm), included some aggressive assumptions about FDA approvals and timeframes, and came up with something like a $75 (USD MESO) per share valuation. Since that time more trials have progressed, some with spectacular results like CHF, but all failing FDA approval on what I would consider to be "technicalities" and/or outright disdain for stem cell treatments by the approving authorities.

my current view is that the actual expected value of the future earnings remains very high and the results from the trials, while missing the approval triggering endpoints, are indicative of even greater probability for product approvals in the near term. the indicated efficacy from the trials is so good and the potential impact on so large a group of patients that these therapies will not be ignored by the medical community or its approving authorities.

what we are seeing currently with the rapid MSB/MESO price erosion is primarily a general financial risk-off movement of overall global markets. it does not change the fundamental value of the firm, which I consider to remain largely unchanged and potentially improved from my prior analysis.

I remember the big swings in MSB/MESO price as the aGVHD trial completed and the FDA evaluated results and eventually denied approval, in opposition to the recommendations of the advisory committee. this price movement was in relation to a very small market (children with steroid refractory acute graft vs host disease). of course the expectation was for much more to come. i think that if and when we see some of these large market approvals hit, like chronic heart failure (CHF), the price swings upward will be multiples of what was seen with aGVHD.

so I remain positive on the firm and continue to hold and view the current price as a great buying opportunity for those willing to hold through the medium term.

of course, we could see a capital raise because, after all, there is no income. but capital raises often occur after positive news is released and price increases.

my other concern is that competitive products may come to market as trials are completed with possible superior efficacy. that could diminish market potential, but only in those markets where similar trials are conducted.

just my thoughts for the day.

Expand

What impact does a capital raise at say 10c have on your valuation? How much do you think they will raise and at what price?

That is, assuming they can get sufficient funding at all which will be incredibly difficult in this market. A really big assumption.

MSB Price at posting: 65.5¢ Sentiment: Sell Disclosure: Not Held
5 Upvote

0 Great analysis

Reply

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

There are more pages in this discussion • 140 more messages in this thread...

First 843 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Mesoblast in Freefall, page-843

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Mesoblast in Freefall, page-843

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News